

BEST AVAILABLE COPY

Modified Form 1449/PTO		Application Number	10/632,340
		Filing Date	August 1, 2003
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		First Named Inventor	Cornelia J. Forster
		Group Art Unit	1624
		Examiner Name	Venkataraman Balasubramanian
		Attorney Docket Number	VPI/02-119 US

U.S. PATENT DOCUMENTS						
Exam Initials	Cite No.	U.S. Patent Document No.	Publication Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
(W)	C1	Gary W. Clint et al, "Effects of a Novel Glycogen Synthase Kinase-3 Inhibitor on Insulin-Stimulated Glucose Metabolism in Zucker Diabetic Fatty (fa/fa) Rats", Diabetes, 51: 2903-2910 (2002)
(W)	C2	Erik J. Henriksen et al, "Modulation of Muscle Insulin Resistance by Selective Inhibition of GSK-3 in Zucker Diabetic Fatty Rats", American Journal of Physiology Endocrinology and Metabolism, 284: E892-E900 (2003).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application.
 U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation,
 continuation-in-part, and divisional applications).

Examiner Signature	V. Balasubramanian	Date Considered	314/106
--------------------	--------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.